{
  "issued_date": "2011-10-26", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON132084", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL (11)A/25", 
    "Audience": "Healthcare professionals", 
    "Published": "26 October 2011", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "2", 
    "Price": "Free", 
    "ISBN/ISSN": "None", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 1 Drug Alert (Action now \u2013 including out of hours): Eli Lilly and Co Ltd - Xigris 5 mg and 20 mg - EL (11)A/25 (67Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/drugalert/con132085.pdf", 
      "filename": "downloads/355bb7b602020dcb02790d0e01edf85fb8c2e9c1/con132085.pdf", 
      "original_filename": "con132085.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 1 MEDICINES RECALL \n\nFor immediate action    \nRecall to hospital and wholesaler level   \n  \n26 October 2011  |   |  EL (11)A/25  |   |  Our ref:\u00a0 MDR 46-10/11   | \n\n* * *\n\nDear Healthcare Professional,\n\nEli Lilly and Co Ltd\n\nXigris 5 mg and 20 mg - Powder for solution for infusion\n\nDrotrecogin alfa (activated)\n\nEU/1/02/225/001-002\n\nImmediate withdrawal of all distributed stock\n\nEli Lilly has informed us that all distributed stock of Xigris is being recalled following discussions with the European Medicines Agency. This action is being taken following new clinical trial findings which show a lack of efficacy and call into question the risk-benefit profile of the product. Specifically, this relates to the results from the PROWESS-SHOCK study, where overall 28-day mortality in Xigris-treated patients (N=846) was 26.4% compared to 24.2% in the placebo control group (N=834); (p=0.31, RR=1.09 [0.92-1.28]).\n\nPatients currently being treated with Xigris should have treatment discontinued. No new patient treatment should be initiated. For further medical information please call Eli Lilly Medical Information on 01256 315000.\n\nSuspected adverse reactions should be reported to the MHRA by use of a Yellow Card, which is available from MHRA, Freepost Yellow Card or electronically via <http://www.mhra.gov.uk/yellowcard>\n\nAny unused stock should be returned to the original supplier for credit. For enquiries related to product returns please call 0800 012 1178.\n\nRecipients of this drug alert are requested to forward this to recipients listed in the central title at the start of the document as promptly as possible. We understand this is a hospital-only product not likely to be used by community pharmacists or general practitioners.\n\nYours sincerely\n\nIan Holloway  \nMHRA DMRC Manager\n\nMHRA Distribution (further recipients by cascade):  Regional contacts for NHS trusts and provider units   \nChief pharmacists: England, Scotland, Wales, Northern Ireland   \nPrison Health Policy Unit (DH)   \nChief pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar   \nSpecial Hospitals   \nHealthcare Commission for distribution to Independent Health Care Establishments   \nPrimary care trusts (England) \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\tCLASS 1 MEDICINES RECALL\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\tFor immediate action\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\tRecall to hospital and wholesaler level\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t26 October 2011\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL (11)A/25\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\tMDR 46-10/11\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Eli Lilly and Co Ltd</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Xigris 5 mg and 20 mg - Powder for solution for infusion</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Drotrecogin alfa (activated)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>EU/1/02/225/001-002</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON132084 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p></p><p><font size=\"4\"><span>Immediate withdrawal of all distributed stock</span></font></p><p>Eli Lilly has informed us that all distributed stock of Xigris is being recalled following discussions with the European Medicines Agency. This action is being taken following new clinical trial findings which show a lack of efficacy and call into question the risk-benefit profile of the product. Specifically, this relates to the results from the PROWESS-SHOCK study, where overall 28-day mortality in Xigris-treated patients (N=846) was 26.4% compared to 24.2% in the placebo control group (N=834); (p=0.31, RR=1.09 [0.92-1.28]).</p><p>Patients currently being treated with Xigris should have treatment discontinued. No new patient treatment should be initiated. For further medical information please call Eli Lilly Medical Information on 01256 315000.</p><p>Suspected adverse reactions should be reported to the MHRA by use of a Yellow Card, which is available from MHRA, Freepost Yellow Card or electronically via <a href=\"http://www.mhra.gov.uk/yellowcard\">http://www.mhra.gov.uk/yellowcard</a></p><p>Any unused stock should be returned to the original supplier for credit. For enquiries related to product returns please call 0800 012 1178.</p><p>Recipients of this drug alert are requested to forward this to recipients listed in the central title at the start of the document as promptly as possible. We understand this is a hospital-only product not likely to be used by community pharmacists or general practitioners.</p><p>Yours sincerely</p><p>Ian Holloway<br>MHRA DMRC Manager</p>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\tRegional contacts for NHS trusts and provider units <br>Chief pharmacists: England, Scotland, Wales, Northern Ireland <br>Prison Health Policy Unit (DH) <br>Chief pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar <br>Special Hospitals <br>Healthcare Commission for distribution to Independent Health Care Establishments <br>Primary care trusts (England)\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON132084 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON132084/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 2 -->\r\n\t<!-- <br>nNumRecords: 2 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`Column 1` <OR>  dDocName <matches>`CON132085` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 1 Drug Alert (Action now \u2013 including out of hours): Eli Lilly and Co Ltd - Xigris 5 mg and 20 mg - EL (11)A/25", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": [
    "pharmacy"
  ]
}